Acumen Pharmaceuticals News

Express News | Watching Eledon Pharmaceuticals, Acumen Pharmaceuticals; Shares See Volume On TipRanks Article Titled "These 2 'Strong Buy' Penny Stocks Are Poised for Over 300% Gains, Say Analysts"

Moomoo 24/7Apr 18 11:41 ET

Acumen Pharmaceuticals Presents First Comprehensive Clinical And Biomarker Data For Sabirnetug At American Academy Of Neurology 2024 Annual Meeting

Presentation and poster include deeper data insights on sabirnetug safety profile, target engagement and fluid biomarker changesPresentation to be featured during AAN Emerging Science SessionCompany o

BenzingaApr 16 08:17 ET

13 Best Penny Stocks to Buy According to Billionaire Ken Griffin

Yahoo FinanceApr 8 17:38 ET

Lonza Enters Manufacturing Agreement for Acumen's Alzheimer's Disease Drug Candidate

Lonza Group (LONN.SW) and Acumen Pharmaceuticals signed a clinical development and commercialization deal for the latter's sabirnetug drug candidate, which is being studied for the treatment of Alzhei

MT NewswiresApr 4 11:35 ET

Express News | Acumen Pharmaceuticals Collaborates With Lonza Covering The Manufacture Of Sabirnetug (ACU193) For Alzheimer's Disease, For Clinical Development And Commercialization, If Approved

Moomoo 24/7Apr 4 08:03 ET

Analysts Offer Insights on Healthcare Companies: LAVA Therapeutics (LVTX), Acumen Pharmaceuticals (ABOS) and Advanced Medical Solutions (GB:AMS)

TipRanksApr 3 05:10 ET

Acumen Pharmaceuticals (ABOS) Upgraded to Buy: What Does It Mean for the Stock?

Yahoo FinanceMar 28 12:00 ET

Acumen Pharmaceuticals Files for $200M Mixed Shelf Offering

Seeking AlphaMar 27 16:58 ET

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q4 2023 Earnings Call Transcript

Yahoo FinanceMar 27 09:46 ET

HC Wainwright & Co. Maintains Buy on Acumen Pharmaceuticals, Maintains $15 Price Target

HC Wainwright & Co. analyst Andrew Fein maintains Acumen Pharmaceuticals with a Buy and maintains $15 price target.

Analyst UpgradesMar 27 09:22 ET

Acumen Pharmaceuticals Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/27/2024 301.07% HC Wainwright & Co. $15 → $15 Maintains Buy 12/12/2023 113.9% Deutsche Bank → $8 Initia

BenzingaMar 27 09:16 ET

Buy Rating Affirmed for Acumen Pharmaceuticals Amid Promising Alzheimer's Treatment Development and Attractive Valuation

TipRanksMar 27 05:06 ET

Q4 2023 Acumen Pharmaceuticals Inc Earnings Call

Yahoo FinanceMar 26 21:20 ET

Express News | Acuen Pharmaceuticals Shares Are Trading Lower After the Company Reported Worse-than-expected Q4 EPS Results

Moomoo 24/7Mar 26 12:41 ET

Earnings Call Summary | Acumen Pharmaceuticals(ABOS.US) Q4 2023 Earnings Conference

The following is a summary of the Acumen Pharmaceuticals, Inc. (ABOS) Q4 2023 Earnings Call Transcript:Financial Performance:Acumen Pharmaceuticals ended 2023 with cash and marketable securities worth

moomoo AIMar 26 11:12 ET · Conference Call

Express News | Acumen Pharmaceuticals Q4 EPS $(0.29) Misses $(0.26) Estimate

Moomoo 24/7Mar 26 09:28 ET

Express News | Acumen Pharmaceuticals FY23 EPS $(1.08) Down From $(1.06) YoY; Cash, Cash Equivalents And Marketable Securities $306.1M

Moomoo 24/7Mar 26 07:08 ET

Acumen Pharmaceuticals GAAP EPS of -$1.08

Seeking AlphaMar 26 07:03 ET

Press Release: Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights -- Initiation of a Phase 2 study, ALTITUDE-AD, to investigate sabirnetug (ACU193

Dow JonesMar 26 07:00 ET

Earnings Scheduled For March 26, 2024

Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million. • AIM ImmunoTech (AMEX:AIM) is estimated to report

BenzingaMar 26 04:47 ET